Glycogen synthase kinase-3β regulates fractalkine production by altering its trafficking from Golgi to plasma membrane: implications for Alzheimer’s disease

Cellular and Molecular Life Sciences

Volumn 74, Issue 6, 2017, Pages 1153-1163

  Fuster Matanzo, Almudena ^a,b,c   Jurado Arjona, Jerónimo ^b,c   Benvegnù, Stefano ^b   García, Esther ^b   Martín Maestro, Patricia ^b,c   Gómez Sintes, Raquel ^d   Hernández, Félix ^b,c   Ávila, Jesús ^b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Alzheimer s disease; Fractalkine; Golgi network; GSK 3 ; Rab8

Indexed keywords

1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; FRACTALKINE; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; PROTEIN BINDING; RAB PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REGULATION; FEMALE; GOLGI COMPLEX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ANIMAL; C57BL MOUSE; CELL MEMBRANE; METABOLISM; PROTEIN TRANSPORT; SOLUBILITY; TRANSPORT VESICLE;

ALZHEIMER DISEASE; ANIMALS; CELL MEMBRANE; CHEMOKINE CX3CL1; GLYCOGEN SYNTHASE KINASE 3 BETA; GOLGI APPARATUS; HUMANS; MICE, INBRED C57BL; PROTEIN BINDING; PROTEIN TRANSPORT; RAB GTP-BINDING PROTEINS; SOLUBILITY; TRANSPORT VESICLES;

EID: 84994727922     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-016-2408-6     Document Type: Article

References (39)

1. Woodgett JR (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9:2431
2. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29:95. doi:10.1016/j.tibs.2003.12.004
3. Beurel E, Grieco SF, Jope RS (2015) Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 148:114. doi:10.1016/j.pharmthera.2014.11.016
4. Hernandez F, Nido JD, Avila J, Villanueva N (2009) GSK3 inhibitors and disease. Mini Rev Med Chem 9:1024
5. Leroy K, Yilmaz Z, Brion JP (2007) Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33:43. doi:10.1111/j.1365-2990.2006.00795.x
6. Pan Y, Lloyd C, Zhou H et al (1997) Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 387:611. doi:10.1038/42491
7. Imaizumi T, Yoshida H, Satoh K (2004) Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 11:15
8. Garton KJ, Gough PJ, Blobel CP et al (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276:37993. doi:10.1074/jbc.M106434200
9. Hundhausen C, Misztela D, Berkhout TA et al (2003) The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1(fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 102:1186. doi:10.1182/blood-2002-12-3775
10. Cook A, Hippensteel R, Shimizu S, Nicolai J, Fatatis A, Meucci O (2010) Interactions between chemokines: regulation of fractalkine/CX3CL1 homeostasis by SDF/CXCL12 in cortical neurons. J Biol Chem 285:10563. doi:10.1074/jbc.M109.035477
11. Fong AM, Robinson LA, Steeber DA et al (1998) Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188:1413
12. Bazan JF, Bacon KB, Hardiman G et al (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385:640. doi:10.1038/385640a0
13. Corcione A, Ferretti E, Bertolotto M et al (2009) CX3CR1 is expressed by human B lymphocytes and mediates CX3CL1 driven chemotaxis of tonsil centrocytes. PLoS One 4:e8485. doi:10.1371/journal.pone.0008485
14. Harrison JK, Jiang Y, Chen S et al (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 95:10896
15. Ferretti E, Pistoia V, Corcione A (2014) Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies. Mediators Inflamm 2014:480941. doi:10.1155/2014/480941
16. Lee S, Varvel NH, Konerth ME et al (2010) CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol 177:2549. doi:10.2353/ajpath.2010.100265
17. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT (2010) Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68:19. doi:10.1016/j.neuron.2010.08.023
18. Stuart MJ, Baune BT (2014) Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev 42:93. doi:10.1016/j.neubiorev.2014.02.001
19. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20:27. doi:10.1093/emboj/20.1.27
20. Martinez-Martin P, Avila J, Investigators ADRU (2010) Alzheimer Center Reina Sofia Foundation: fighting the disease and providing overall solutions. J Alzheimers Dis 21:337. doi:10.3233/JAD-2010-101149
21. International Society for Biological and Environmental Repositories Biopreservation and Biobanking 2012. Collection, retrieval, and distribution of, bmf research (2008) Cell Preserv Technol 6. doi:10.1089/cpt.2008.9997
22. Bhat R, Xue Y, Berg S et al (2003) Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278:45937. doi:10.1074/jbc.M306268200
23. Wilson C, Venditti R, Rega LR, Colanzi A, D’Angelo G, De Matteis MA (2011) The Golgi apparatus: an organelle with multiple complex functions. Biochem J 433:1. doi:10.1042/BJ20101058
24. Adachi A, Kano F, Tsuboi T, Fujita M, Maeda Y, Murata M (2010) Golgi-associated GSK3beta regulates the sorting process of post-Golgi membrane trafficking. J Cell Sci 123:3215. doi:10.1242/jcs.063941
25. Hutagalung AH, Novick PJ (2011) Role of Rab GTPases in membrane traffic and cell physiology. Physiol Rev 91:119. doi:10.1152/physrev.00059.2009
26. Huber LA, Pimplikar S, Parton RG, Virta H, Zerial M, Simons K (1993) Rab8, a small GTPase involved in vesicular traffic between the TGN and the basolateral plasma membrane. J Cell Biol 123:35
27. Engel T, Hernandez F, Avila J, Lucas JJ (2006) Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26:5083. doi:10.1523/JNEUROSCI.0604-06.2006
28. Lei P, Ayton S, Bush AI, Adlard PA (2011) GSK-3 in Neurodegenerative Diseases. Int J Alzheimers Dis 2011:189246. doi:10.4061/2011/189246
29. Hernandez F, Lucas JJ, Avila J (2013) GSK3 and tau: two convergence points in Alzheimer's disease. J Alzheimers Dis 33(Suppl 1):S141. doi:10.3233/JAD-2012-129025
30. Klute MJ, Melancon P, Dacks JB (2011) Evolution and diversity of the Golgi. Cold Spring Harb Perspect Biol 3:a007849. doi:10.1101/cshperspect.a007849
31. Chen HJ, Lin CM, Lin CS, Perez-Olle R, Leung CL, Liem RK (2006) The role of microtubule actin cross-linking factor 1 (MACF1) in the Wnt signaling pathway. Genes Dev 20:1933. doi:10.1101/gad.1411206
32. Tang D, Wang Y (2013) Cell cycle regulation of Golgi membrane dynamics. Trends Cell Biol 23:296. doi:10.1016/j.tcb.2013.01.008
33. Zhang X, Wang Y (2015) GRASPs in Golgi Structure and Function. Front Cell Dev Biol 3:84. doi:10.3389/fcell.2015.00084
34. Zhang B, Zhang T, Wang G et al (2015) GSK3beta-Dzip1-Rab8 cascade regulates ciliogenesis after mitosis. PLoS Biol 13:e1002129. doi:10.1371/journal.pbio.1002129
35. Diniz BS, Machado-Vieira R, Forlenza OV (2013) Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat 9:493. doi:10.2147/NDT.S33086
36. Iqbal K, Grundke-Iqbal I (2010) Alzheimer's disease, a multifactorial disorder seeking multitherapies. Alzheimers Dement 6:420. doi:10.1016/j.jalz.2010.04.006
37. Manzine PR, de Franca Bram JM, Barham EJ et al (2013) ADAM10 as a biomarker for Alzheimer's disease: a study with Brazilian elderly. Dement Geriatr Cogn Disord 35:58. doi:10.1159/000345983
38. Kim TS, Lim HK, Lee JY et al (2008) Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 436:196. doi:10.1016/j.neulet.2008.03.019
39. Lauro C, Catalano M, Trettel F, Limatola C (2015) Fractalkine in the nervous system: neuroprotective or neurotoxic molecule? Ann N Y Acad Sci 1351:141. doi:10.1111/nyas.12805